Constellation Pharmaceuticals, Inc.

États‑Unis d’Amérique

Retour au propriétaire

1-34 de 34 pour Constellation Pharmaceuticals, Inc.

Trier par

Recheche Texte

Marque

Affiner par

Reset Report

Juridiction

Date

Classe NICE

Statut

Résultats pour

marques

1. PELLMOFI

Numéro d'application	1834619
Statut	Enregistrée
Date de dépôt	2024-09-30
Date d'enregistrement	2024-09-30
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

2. PELLMOFY

Numéro d'application	1834620
Statut	Enregistrée
Date de dépôt	2024-09-30
Date d'enregistrement	2024-09-30
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

3.

Miscellaneous Design

Numéro de série	98840849
Statut	En instance
Date de dépôt	2024-11-06
Propriétaire	Constellation Pharmaceuticals, Inc. ()
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceutical preparations comprising small molecules for treating cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; small molecule pharmaceuticals for the treatment of diseases and conditions, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies sold as a component ingredient of pharmaceuticals for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; diagnostic preparations for medical purposes; clinical medical reagents; biological preparations for medical purposes, namely for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceutical and veterinary preparations and agents for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways

4.

Miscellaneous Design

Numéro de série	98840863
Statut	En instance
Date de dépôt	2024-11-06
Propriétaire	Constellation Pharmaceuticals, Inc. ()
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

5.

Miscellaneous Design

Numéro de série	98840878
Statut	En instance
Date de dépôt	2024-11-06
Propriétaire	Constellation Pharmaceuticals, Inc. ()
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

6. PELLMOFY

Numéro d'application	237570000
Statut	En instance
Date de dépôt	2024-09-30
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

(1) Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceuticals comprising small molecules; small molecule compounds for medical use and drug delivery; small molecule pharmaceuticals for the treatment of diseases and conditions; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders; antibodies sold as a component ingredient of pharmaceuticals; diagnostic preparations for medical purposes; biological substances for human medical diagnostics and analysis; clinical medical reagents; biological preparations for medical purposes; pharmaceutical and veterinary preparations, agents and substances.

7. PELLMOFI

Numéro d'application	237569900
Statut	En instance
Date de dépôt	2024-09-30
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

8. PELLMOFI

Numéro d'application	019012072
Statut	Enregistrée
Date de dépôt	2024-04-11
Date d'enregistrement	2024-08-31
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

9. PELLMOFY

Numéro d'application	019012205
Statut	Enregistrée
Date de dépôt	2024-04-11
Date d'enregistrement	2024-08-31
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

10. PELLMOFI

Numéro de série	98479628
Statut	En instance
Date de dépôt	2024-04-02
Propriétaire	Constellation Pharmaceuticals, Inc. ()
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceutical preparations comprising small molecules for treating cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; small molecule pharmaceuticals for the treatment of diseases and conditions, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies sold as a component ingredient of pharmaceuticals for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; diagnostic preparations for medical purposes; clinical medical reagents; biological preparations for medical purposes, namely for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceutical and veterinary preparations, and agents for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways

11. PELLMOFY

Numéro de série	98479643
Statut	En instance
Date de dépôt	2024-04-02
Propriétaire	Constellation Pharmaceuticals, Inc. ()
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceutical preparations comprising small molecules for treating cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; small molecule pharmaceuticals for the treatment of diseases and conditions, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies sold as a component ingredient of pharmaceuticals for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; diagnostic preparations for medical purposes; clinical medical reagents; biological preparations for medical purposes, namely for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceutical and veterinary preparations, and agents for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways

12. PELMOFY

Numéro d'application	1757750
Statut	Enregistrée
Date de dépôt	2023-08-02
Date d'enregistrement	2023-08-02
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

13. BETPELMY

Numéro d'application	1758006
Statut	Enregistrée
Date de dépôt	2023-08-02
Date d'enregistrement	2023-08-02
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

14. PELAMOFY

Numéro d'application	1757751
Statut	Enregistrée
Date de dépôt	2023-08-02
Date d'enregistrement	2023-08-02
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

15. BETFIRSO

Numéro d'application	1758004
Statut	Enregistrée
Date de dépôt	2023-08-02
Date d'enregistrement	2023-08-02
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

16. PELMOFY

Numéro d'application	228912500
Statut	En instance
Date de dépôt	2023-08-02
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

(1) Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, bromodomain and extra-terminal (BET) protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceuticals comprising small molecules; small molecule compounds for medical use and drug delivery; small molecule pharmaceuticals for the treatment of diseases and conditions; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders; antibodies sold as a component ingredient of pharmaceuticals; diagnostic preparations for medical purposes; biological substances for human medical diagnostics and analysis; clinical medical reagents; biological preparations for medical purposes; pharmaceutical and veterinary preparations, agents and substances.

17. BETPELMY

Numéro d'application	228912700
Statut	En instance
Date de dépôt	2023-08-02
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

18. BETFIRSO

Numéro d'application	228912800
Statut	En instance
Date de dépôt	2023-08-02
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

19. PELAMOFY

Numéro d'application	228912600
Statut	En instance
Date de dépôt	2023-08-02
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

(1) Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, bromodomain and extra-terminal (BET) protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceuticals comprising small molecules; small molecule compounds for medical use and drug delivery; small molecule pharmaceuticals for the treatment of diseases and conditions; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders; antibodies sold as a component ingredient of pharmaceuticals; diagnostic preparations for medical purposes; biological substances for human medical diagnostics and analysis; clinical medical reagents; biological preparations for medical purposes; pharmaceutical and veterinary preparations, agents and substances.

20. BETFIRSO

Numéro d'application	018836370
Statut	Enregistrée
Date de dépôt	2023-02-15
Date d'enregistrement	2023-09-28
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Antibodies sold as a component ingredient of pharmaceuticals; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines. Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceuticals comprising small molecules; small molecule compounds for medical use and drug delivery; small molecule pharmaceuticals for the treatment of diseases and conditions; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders; diagnostic preparations for medical purposes; biological substances for human medical diagnostics and analysis; clinical medical reagents; biological preparations for medical purposes; pharmaceutical and veterinary preparations, agents and substances.

21. BETPELMY

Numéro d'application	018836408
Statut	Enregistrée
Date de dépôt	2023-02-15
Date d'enregistrement	2023-08-22
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

22. BETMOFY

Numéro d'application	018836422
Statut	Enregistrée
Date de dépôt	2023-02-15
Date d'enregistrement	2023-08-22
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

23. PELAMOFY

Numéro d'application	018836402
Statut	Enregistrée
Date de dépôt	2023-02-15
Date d'enregistrement	2023-08-22
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

24. PELMOFY

Numéro d'application	018836425
Statut	Enregistrée
Date de dépôt	2023-02-15
Date d'enregistrement	2023-08-22
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

25. PELAMOFY

Numéro de série	97786656
Statut	En instance
Date de dépôt	2023-02-08
Propriétaire	Constellation Pharmaceuticals, Inc. ()
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceutical preparations comprising small molecules for treating cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; small molecule pharmaceuticals for the treatment of diseases and conditions, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies sold as a component ingredient of pharmaceuticals for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; diagnostic preparations for medical purposes; clinical medical reagents; biological preparations for medical purposes, namely for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceutical and veterinary preparations and agents for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways

26. BETMOFY

Numéro de série	97786664
Statut	En instance
Date de dépôt	2023-02-08
Propriétaire	Constellation Pharmaceuticals, Inc. ()
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceutical preparations comprising small molecules for treating cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; small molecule pharmaceuticals for the treatment of diseases and conditions, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies sold as a component ingredient of pharmaceuticals for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; diagnostic preparations for medical purposes; clinical medical reagents; biological preparations for medical purposes, namely for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceutical and veterinary preparations and agents for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways

27. BETFIRSO

Numéro de série	97786648
Statut	En instance
Date de dépôt	2023-02-08
Propriétaire	Constellation Pharmaceuticals, Inc. ()
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceutical preparations comprising small molecules for treating cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; small molecule pharmaceuticals for the treatment of diseases and conditions, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies sold as a component ingredient of pharmaceuticals for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; diagnostic preparations for medical purposes; clinical medical reagents; biological preparations for medical purposes, namely for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceutical and veterinary preparations and agents for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways

28. PELMOFY

Numéro de série	97786669
Statut	En instance
Date de dépôt	2023-02-08
Propriétaire	Constellation Pharmaceuticals, Inc. ()
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceutical preparations comprising small molecules for treating cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; small molecule pharmaceuticals for the treatment of diseases and conditions, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies sold as a component ingredient of pharmaceuticals for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; diagnostic preparations for medical purposes; clinical medical reagents; biological preparations for medical purposes, namely for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceutical and veterinary preparations and agents for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways

29.

Constellation Pharmaceuticals

Numéro d'application	017971710
Statut	Enregistrée
Date de dépôt	2018-10-23
Date d'enregistrement	2019-04-18
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques 42 - Services scientifiques, technologiques et industriels, recherche et conception

Produits et services

Pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer, inflammatory, and fibrotic disorders; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics. Pharmaceutical research and development; Research and development in the fields of genetics, pharmaceuticals, cancer, epigenetics, and immune-oncology; conducting early evaluations in the field of new pharmaceuticals; development of pharmaceutical preparations and medicines; pharmaceutical products development.

30. CONSTELLATION

Numéro d'application	017971720
Statut	Enregistrée
Date de dépôt	2018-10-23
Date d'enregistrement	2019-04-18
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques 42 - Services scientifiques, technologiques et industriels, recherche et conception

Produits et services

31.

CONSTELLATION PHARMACEUTICALS

Numéro d'application	192656900
Statut	Enregistrée
Date de dépôt	2018-10-23
Date d'enregistrement	2022-07-27
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques 42 - Services scientifiques, technologiques et industriels, recherche et conception

Produits et services

(1) Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of hematologic diseases and disorders, autoimmune diseases and disorders, and inflammatory diseases and disorders; pharmaceutical preparations for the treatment myelofibrosis, rheumatoid arthritis, irritable bowel syndrome, psoriasis, and sepsis; pharmaceutical preparations for the treatment of cancer, inflammatory diseases and disorders, and fibrotic disorders; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics. (1) Pharmaceutical research and development; Research and development in the fields of genetics, pharmaceuticals, cancer, epigenetics, and immune-oncology; conducting early evaluations in the field of new pharmaceuticals; development of pharmaceutical preparations and medicines; pharmaceutical products development.

32. CONSTELLATION

Numéro d'application	192657000
Statut	Enregistrée
Date de dépôt	2018-10-23
Date d'enregistrement	2022-07-27
Propriétaire	Constellation Pharmaceuticals, Inc. (USA)
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques 42 - Services scientifiques, technologiques et industriels, recherche et conception

Produits et services

33. CONSTELLATION

Numéro de série	87888540
Statut	En instance
Date de dépôt	2018-04-23
Propriétaire	Constellation Pharmaceuticals, Inc. ()
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques 42 - Services scientifiques, technologiques et industriels, recherche et conception

Produits et services

Pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of cancer, inflammatory, and fibrotic disorders; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceutical preparations for the treatment of lymphomia, solid cancers, blood disease, myelofibrosis, Alzheimer's disease, arthritis, Sjogren's syndrome, autoimmune hepatitis, systemic lupus erythematosus, venus thromboembolism (VTE), cancer associated thrombosis (CAT), renal autoimmune disease, pulmonary sarcoidosis, severe atopic dermatitis, diabetes, asthma, chronic obstructive pulmonary disease (COPD) Pharmaceutical research and development; Research and development in the fields of genetics, pharmaceuticals, cancer, epigenetics, and immune-oncology, all of the foregoing for the purposes of drug development; conducting early evaluations in the field of new pharmaceuticals; development of pharmaceutical preparations and medicines; pharmaceutical products development

34.

CONSTELLATION PHARMACEUTICALS

Numéro de série	87888556
Statut	En instance
Date de dépôt	2018-04-23
Propriétaire	Constellation Pharmaceuticals, Inc. ()
Classes de Nice ?	05 - Produits pharmaceutiques, vétérinaires et hygièniques 42 - Services scientifiques, technologiques et industriels, recherche et conception

Produits et services